Recent Publications

List of most recent publications led by the Sant Pau Memory Unit:

  1. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Alcolea, D, Beeri, MS, Rojas, JC et al. Neurology 2023

  2. Correction: Cortical microstructure in primary progressive aphasia: a multicenter study. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Alzheimers Res Ther 2023

  3. Amyloid precursor protein 𝛽CTF accumulates in synapses in sporadic and genetic forms of Alzheimer's disease. Ferrer-Raventós, P, Puertollano-Martín, D, Querol-Vilaseca, M et al. Neuropathol Appl Neurobiol 2023

  4. Early Motor Changes in Genetic Frontotemporal Dementia. Lleó, A, Illán-Gala, I Neurology 2022

  5. Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease. Benejam, B, Aranha, MR, Videla, L et al. Alzheimers Res Ther 2022

  6. Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma. Valle-Tamayo, N, Pérez-González, R, Chiva-Blanch, G et al. J Vis Exp 2022

  7. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome. Videla, L, Benejam, B, Pegueroles, J et al. JAMA Netw Open 2022

  8. Myelin loss in C9orf72 hexanucleotide expansion carriers. Sirisi, S, Querol-Vilaseca, M, Dols-Icardo, O et al. J Neurosci Res 2022

  9. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. Iulita, MF, Garzón Chavez, D, Klitgaard Christensen, M et al. JAMA Netw Open 2022

  10. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. Illán-Gala, I, Nigro, S, VandeVrede, L et al. JAMA Netw Open 2022

  11. Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease. Aranha, MR, Fortea, J, Carmona-Iragui, M et al. Neurology 2022

  12. Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications. Altuna, M, Olmedo-Saura, G, Carmona-Iragui, M et al. Int J Mol Sci 2022

  13. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Cervantes González, A, Irwin, DJ, Alcolea, D et al. Mol Neurodegener 2022

  14. Fluid markers of synapse degeneration in synucleinopathies. Cervantes González, A, Belbin, O J Neural Transm (Vienna) 2022

  15. Cortical microstructure in primary progressive aphasia: a multicenter study. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Alzheimers Res Ther 2022

  16. Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Reyes-Leiva, D, Dols-Icardo, O, Sirisi, S et al. Front Neurol 2021

  17. The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone. Delaby, C, Estellés, T, Zhu, N et al. Alzheimers Res Ther 2022

  18. [Preliminary study of the temporal variables of continuous speech in patients with neurodegenerative syndromes of the frontotemporal lobar degeneration spectrum]. Baqué, L, Machuca, MJ, Santos-Santos, MA et al. Rev Neurol 2022

  19. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Zhu, N, Santos-Santos, M, Illán-Gala, I et al. Transl Neurodegener 2021

  20. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Querol-Vilaseca, M, Sirisi, S, Molina-Porcel, L et al. Neuropathol Appl Neurobiol 2022

  21. Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Fortea, J, Zaman, SH, Hartley, S et al. Lancet Neurol 2021

  22. The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery : NGF Pathway Biomarkers and Drug Targets. Pentz, R, Iulita, MF Adv Exp Med Biol 2021

  23. Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. Montal, V, Barroeta, I, Bejanin, A et al. Ann Neurol 2021

  24. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Carmona-Iragui, M, Alcolea, D, Barroeta, I et al. Lancet Neurol 2021

  25. Sleep Disorders in Adults with Down Syndrome. Giménez, S, Altuna, M, Blessing, E et al. J Clin Med 2021

  26. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Lleó, A, Zetterberg, H, Pegueroles, J et al. Nat Commun 2021

  27. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. Bejanin, A, Iulita, MF, Vilaplana, E et al. JAMA Neurol 2021

  28. Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. Altuna, M, Giménez, S, Fortea, J et al. J Clin Med 2021

  29. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Lleó, A, Carmona-Iragui, M, Videla, L et al. Alzheimers Res Ther 2021

  30. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Alcolea, D, Delaby, C, Muñoz, L et al. J Neurol Neurosurg Psychiatry 2021

Search PubMed